Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

idarucizumab

- PMLiVE

Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

The deal focuses on T cell-based therapies for autoimmune disease

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

EU flag

EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

- PMLiVE

Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

- PMLiVE

Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials

The candidate is currently under review for both interstitial lung diseases in the EU and US

- PMLiVE

Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

The companies will focus on developing treatments for hard-to-treat ALT-positive tumours

- PMLiVE

FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

- PMLiVE

Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

- PMLiVE

Boehringer Ingelheim and Salipro Biotech enter drug development partnership

The companies will focus on targeting proteins in areas such as cardio-renal-metabolic diseases

- PMLiVE

World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

Approximately 10% of the UK population is affected by chronic kidney disease

EU flag

EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links